Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Antibody coated stent a breakthrough in cardiovascular treatment


An innovative medical discovery that has the potential to vastly improve the lives of people suffering from coronary artery disease was implanted today in the first human patient. The antibody coated stent, developed by Dr. Michael Kutryk, a cardiologist and clinician scientist with St. Michael’s Hospital and assistant professor, University of Toronto, was implanted into the first human patient at Thoraxcenter, University Hospital Rotterdam in Holland. The procedure was transmitted via a live feed to the EuroPCR Conference in Paris, France - a conference of over 10,000 interventional cardiologists.

Stents are wire mesh tubes that have been used for years in interventional cardiology to clear blocked arteries and to improve the flow of blood to the heart muscle. However, traditional stents have been known to cause restenosis (re-narrowing of the artery in a treated area) and can lead to blood clots. Kutryk’s invention of the antibody coated stent reduces restenosis and prevents blood clots from occurring.

"This is a very exciting time to be working in the field of interventional cardiology," says Dr. Kutryk. "When animal trials showed that antibody coated stents were successful in promoting healing and preventing restenosis, we knew this could potentially impact a large number of patients suffering from coronary artery disease."

"If the implantation of the coated stent works in humans like it has in animals, it will be one of the biggest advances in cardiology we have seen to date," says Dr. Patrick Serruys, cardiologist, University Hospital Rotterdam. "We have been calling Dr. Kutryk’s research a glimpse into the future. Today, that future is here."

When placed into a blocked area of an artery, the antibody coated stent captures endothelial progenitor cells (EPC) circulating throughout the blood. Endothelial cells are cells which line blood vessels, allowing blood to flow smoothly.

The EPCs adhere to the hard surface of the stent forming a smooth layer that not only promotes healing but prevents restenosis (re-narrowing of the artery) and blood clots, complications previously associated with the use of stents.

"We are expecting to perform the first operation of a stent on a North American patient at St. Michael’s Hospital sometime in early June," said Kutryk. "Once we determine the effectiveness of using the antibody coated stents, we will be examining other ways that this discovery can be used to improve clinical outcomes for patients suffering from cardiovascular disease. The implications are enormous."

In addition to improving outcomes for patients requiring stents, there are also implications for patients requiring cardiovascular bypass surgery. For example, a prosthetic vascular conduit (artificial artery) coated with anti-EPC antibodies would eliminate the need to use arteries from patients legs or arms for bypass surgery grafts. This would reduce surgery and anesthesia times which in turn will reduce coronary surgery deaths.

According to the Heart and Stroke Foundation of Canada cardiovascular disease accounted for 78,942 Canadian deaths in 1999 with 54 per cent of cardiovascular deaths from coronary artery disease and an additional 10 per cent of deaths from high blood pressure and hardening of the arteries.

Dr. Kutryk’s research is supported by a grant from ORBUS medical technologies. The company contributed funding the research, but had no input or influence over the research or conduct.

St. Michael’s Hospital is a Catholic teaching and research hospital, fully affiliated with the University of Toronto, specializing in heart and vascular disease, inner city health, trauma/neurosurgery, diabetes comprehensive care, minimal access therapeutics, and neurological and musculoskeletal disorders.

For more information please contact:

Tracy MacIsaac, Media Relations
St. Michael’s Hospital
Telephone: 416-864-5047
Pager: 416-864-5431

Jessica Villanueva, Media Relations
St. Michael’s Hospital
Telephone: 416-864-5034
Pager: 416-864-5431

Tracy MacIsaac | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

Im Focus: Unique Insights into the Antarctic Ice Shelf System

Data collected on ocean-ice interactions in the little-researched regions of the far south

The world’s second-largest ice shelf was the destination for a Polarstern expedition that ended in Punta Arenas, Chile on 14th March 2018. Oceanographers from...

Im Focus: ILA 2018: Laser alternative to hexavalent chromium coating

At the 2018 ILA Berlin Air Show from April 25–29, the Fraunhofer Institute for Laser Technology ILT is showcasing extreme high-speed Laser Material Deposition (EHLA): A video documents how for metal components that are highly loaded, EHLA has already proved itself as an alternative to hard chrome plating, which is now allowed only under special conditions.

When the EU restricted the use of hexavalent chromium compounds to special applications requiring authorization, the move prompted a rethink in the surface...

Im Focus: Radar for navigation support from autonomous flying drones

At the ILA Berlin, hall 4, booth 202, Fraunhofer FHR will present two radar sensors for navigation support of drones. The sensors are valuable components in the implementation of autonomous flying drones: they function as obstacle detectors to prevent collisions. Radar sensors also operate reliably in restricted visibility, e.g. in foggy or dusty conditions. Due to their ability to measure distances with high precision, the radar sensors can also be used as altimeters when other sources of information such as barometers or GPS are not available or cannot operate optimally.

Drones play an increasingly important role in the area of logistics and services. Well-known logistic companies place great hope in these compact, aerial...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

International Virtual Reality Conference “IEEE VR 2018” comes to Reutlingen, Germany

08.03.2018 | Event News

Latest News

Wandering greenhouse gas

16.03.2018 | Earth Sciences

'Frequency combs' ID chemicals within the mid-infrared spectral region

16.03.2018 | Physics and Astronomy

Biologists unravel another mystery of what makes DNA go 'loopy'

16.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>